Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To determine whether pioglitazone influences endothelial function directly, we examined in a randomized, crossover, placebo-controlled, double-blind trial the effects of 4 weeks of pioglitazone treatment in 20 male type 2 diabetic patients. We conclude that short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries irrespective of significant beneficial changes in plasma levels of insulin, FFA, adiponectin, or CRP in type 2 patients with diabetes. Pioglitazone, a PPARgamma agonist, not only improves insulin resistance and glycemic control but may also have additional beneficial vascular effects in patients with type 2 diabetes. Low-grade inflammation, free fatty acids, and adiponectin may play a role in modulation of vascular function. We studied the effect of 4 weeks of pioglitazone treatment on endothelial function, metabolic changes, and C-reactive protein in patients with type 2 diabetes. A randomized, crossover, placebo-controlled, double-blind trial was performed in which pioglitazone 30 mg once daily was administered to 20 patients with type 2 diabetes on oral antihyperglycemic agents for 4 weeks. Shear stress-induced flow-mediated dilation (FMD) of the brachial artery was used as outcome parameter for vascular function. Brachial artery endothelial function was significantly increased by pioglitazone treatment compared with placebo (FMD 5.4 +/- 0.5% versus 3.1 +/- 0.5%, P = 0.001). Endothelium-independent vasodilation was not different between the 2 study periods. Pioglitazone treatment reduced insulin, FFA, and C-reactive protein concentrations compared with placebo (18.3 +/- 2.4 versus 14.8 +/- 2.1 mU/L, P = 0.03; 641 +/- 46 versus 542 +/- 33 mumol/L, P = 0.04; and 3.5 +/- 0.6 mg/L versus 2.6 +/- 0.5 mg/L, P = 0.01; respectively). A significant increase in plasma adiponectin concentration (3.95 +/- 0.57 microg/mL versus 7.59 +/- 0.95 microg/mL, P = 0.002) was also observed. No correlations were found between these metabolic changes and the improvement of conduit artery endothelial function. Short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries irrespective of changes in insulin, FFA, adiponectin, or CRP in type 2 patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Cited by
Balzer, J., Rassaf, T., Heiss, C., Kleinbongard, P., Lauer, T., Merx, M., Heussen, N., Gross, H. B., Keen, C. L., Schroeter, H., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.059 · Cited by 345
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0012 · Cited by 167
Metadata
- Authors
- Martens, F. M. A. C., Visseren, F. L. J., de Koning, E. J. P., & Rabelink, T. J.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2005-12
- Volume
- 46
- Issue
- 6
- Pages
- 773-778
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W1994269792
- Cited by
- 105
- References
- 3
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.1097/01.fjc.0000187176.13403.05
- The paper
- Martens, F. M. A. C., Visseren, F. L. J., de Koning, E. J. P., & Rabelink, T. J. (2005). Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 Diabetes. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/01.fjc.0000187176.13403.05
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.